# US 2021/0332367 A1 · KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332367 A1
- Document ID: US20210332367A1
- Status: Published application
- Kind: A1
- Application number: 17/254,421
- Filed: 2019-09-17
- Published: 2021-10-28
- Earliest claimed: 2018-09-18
- Assignees: Alnylam Pharmaceuticals, Inc.
- Applicants: Alnylam Pharmaceuticals, Inc.
- Inventors: Gregory Hinkle
- Web page: https://patentgrep.com/patent/US20210332367A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2310/351: Conjugate
- C12Y 207/01003: Ketohexokinase (2.7.1.3)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the ketohexokinase (KHK) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a KHK gene and to methods of treating or preventing a KHK-associated disease in a subject.

## Claims

### Claim 1

A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of a ketohexokinase (KHK) gene, wherein the dsRNA agent comprises a sense strand and an antisense strand, wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of any one of nucleotides 89-107, 176-194, 264-282, 474-492, 508-526, 529-547, 562-580, 616-646, 682-700, 705-723, 705-757, 705-799, 739-757, 739-799, 760-799, 804-822, 837-855, 892-910, 959-977, 992-1010, 922-1041, 1013-1041, 1069-1108, 1169-1140, 1111-1140, 1155-1196, 1221-1261, 1267-1294, or 1320-1350 of SEQ ID NO:1, and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:2.

### Claim 2

A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of a ketohexokinase (KHK) gene, wherein the dsRNA agent comprises a sense strand and an antisense strand, the antisense strand comprising a region of complementarity which comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the antisense sequences listed in Table 3 or 5.

### Claim 3 (depends on 2)

The dsRNA agent of claim 2, wherein the antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the antisense sequences in a duplex selected from the group consisting of AD-72506, AD-72319, AD-72502, AD-72513, AD-72499, AD-72303, AD-72500, AD-72522, AD-72512, AD-72304, AD-72514, AD-72257, AD-72295, AD-72332, AD-72507, AD-72311, AD-72501, AD-72508, AD-72293, AD-72322, AD-72264, AD-72290, AD-72338, AD-72315, AD-72272, AD-72337, AD-72298, AD-72503, AD-72327, AD-72521, AD-72309, AD-72313, AD-72517, AD-72316, AD-72335, or AD-72317.

### Claim 4 (depends on 1, 2, 3)

The dsRNA agent of any one of claims 1-3, wherein the sense and antisense strands comprise sequences selected from any of the sequences in Table 3 or 5.

### Claim 5 (depends on 1, 2, 3, 4)

The dsRNA agent of any one of claims 1-4, wherein the dsRNA comprises at least one modified nucleotide.

### Claim 6 (depends on 1, 2, 3, 4)

The dsRNA agent of any one of claims 1-4, wherein all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand comprise a modification.

### Claim 7

A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of a ketohexokinase (KHK) gene, wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region,
wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of any one of nucleotides 89-107, 176-194, 264-282, 474-492, 508-526, 529-547, 562-580, 616-646, 682-700, 705-723, 705-757, 705-799, 739-757, 739-799, 760-799, 804-822, 837-855, 892-910, 959-977, 992-1010, 922-1041, 1013-1041, 1069-1108, 1169-1140, 1111-1140, 1155-1196, 1221-1261, 1267-1294, or 1320-1350 of SEQ ID NO:1 and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:2,
wherein substantially all of the nucleotides of the sense strand and substantially all of the nucleotides of the antisense strand are modified nucleotides, and
wherein the sense strand is conjugated to a ligand attached at the 3′-terminus.

### Claim 8 (depends on 7)

The dsRNA agent of claim 7, wherein all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand comprise a modification.

### Claim 9 (depends on 7)

The dsRNA agent of claim 7, wherein at least one of the modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 3′-terminal deoxy-thymine (dT) nucleotide, a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2′-amino-modified nucleotide, a 2′-O-allyl-modified nucleotide, 2′-C-alkyl-modified nucleotide, 2′-hydroxyl-modified nucleotide, a 2′-methoxyethyl modified nucleotide, a 2′-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5′-phosphate, and a nucleotide comprising a 5′-phosphate mimic.

### Claim 10 (depends on 9)

The dsRNA agent of claim 9, wherein the modified nucleotides comprise a short sequence of 3′-terminal deoxy-thymine nucleotides (dT).

### Claim 11 (depends on 2, 3)

The dsRNA agent of claim 2 or 3, wherein the region of complementarity is at least 17 nucleotides in length.

### Claim 12 (depends on 2, 3)

The dsRNA agent of claim 2 or 3, wherein the region of complementarity is 19-21 nucleotides in length.

### Claim 13 (depends on 12)

The dsRNA agent of claim 12, wherein the region of complementarity is 19 nucleotides in length.

### Claim 14 (depends on 1, 2, 3, 7)

The dsRNA agent of any one of claims 1-3 and 7, wherein each strand is no more than 30 nucleotides in length.

### Claim 15 (depends on 1, 2, 3, 7)

The dsRNA agent of any one of claims 1-3 and 7, wherein at least one strand comprises a 3′ overhang of at least 1 nucleotide.

### Claim 16 (depends on 1, 2, 3, 7)

The dsRNA agent of any one of claims 1-3 and 7, wherein at least one strand comprises a 3′ overhang of at least 2 nucleotides.

### Claim 17 (depends on 1, 2, 3)

The dsRNA agent of any one of claims 1-3 further comprising a ligand.

### Claim 18 (depends on 17)

The dsRNA agent of claim 17, wherein the ligand is conjugated to the 3′ end of the sense strand of the dsRNA agent.

### Claim 19 (depends on 7, 17)

The dsRNA agent of claim 7 or 17, wherein the ligand is an N-acetylgalactosamine (GalNAc) derivative.

### Claim 20 (depends on 19)

The dsRNA agent of claim 19, wherein the ligand is

### Claim 21 (depends on 19)

The dsRNA agent of claim 19, wherein the dsRNA agent is conjugated to the ligand as shown in the following schematic
and, wherein X is O or S.

### Claim 22 (depends on 21)

The dsRNA agent of claim 21, wherein the X is O.

### Claim 23 (depends on 2, 3)

The dsRNA agent of claim 2 or 3, wherein the region of complementarity comprises one of the antisense sequences of Table 3 or 5.

### Claim 24 (depends on 2, 3)

The dsRNA agent of claim 2 or 3, wherein the region of complementarity consists of one of the antisense sequences of Table 3 or 5.

### Claim 25

A double stranded ribonucleic acid (dsRNA) agent for inhibiting the expression of a ketohexokinase (KHK) gene in a cell, wherein the dsRNA agent comprises a sense strand and an antisense strand, wherein the antisense strand comprises a region of complementarity to an mRNA encoding KHK, wherein each strand is about 14 to about 30 nucleotides in length, wherein the dsRNA agent is represented by formula (III):
sense: 5′np-Na—(XXX)i—Nb—YYY—Nb—(ZZZ)j—Na-nq3′
antisense: 3′np′-Na′—(X′X′X′)k—Nb′—Y′Y′Y′—Nb′—(Z′Z′Z′)l—Na′-nq′5′ (III)
wherein:
j, k, and l are each independently 0 or 1;
p, p′, q, and q′ are each independently 0-6;
each Na and Na′ independently represents an oligonucleotide sequence comprising 0-25 nucleotides which are either modified or unmodified or combinations thereof, each sequence comprising at least two differently modified nucleotides;
each Nb and Nb′ independently represents an oligonucleotide sequence comprising 0-10 nucleotides which are either modified or unmodified or combinations thereof;
each np, np′, nq, and nq′, each of which may or may not be present, independently represents an overhang nucleotide;
XXX, YYY, ZZZ, X′X′X′, Y′Y′Y′, and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides;
modifications on Nb differ from the modification on Y and modifications on Nb′ differ from the modification on Y′; and
wherein the sense strand is conjugated to at least one ligand.

### Claim 26 (depends on 25)

The dsRNA agent of claim 25, wherein i is 0; j is 0; i is 1; j is 1; both i and j are 0; or both i and j are 1.

### Claim 27 (depends on 25)

The dsRNA agent of claim 25, wherein k is 0; 1 is 0; k is 1; l is 1; both k and l are 0; or both k and l are 1.

### Claim 28 (depends on 25)

The dsRNA agent of claim 25, wherein XXX is complementary to X′X′X′, YYY is complementary to Y′Y′Y′, and ZZZ is complementary to Z′Z′Z′.

### Claim 29 (depends on 25)

The dsRNA agent of claim 25, wherein the YYY motif occurs at or near the cleavage site of the sense strand.

### Claim 30 (depends on 25)

The dsRNA agent of claim 25, wherein the Y′Y′Y′ motif occurs at the 11, 12 and 13 positions of the antisense strand from the 5′-end.

### Claim 31 (depends on 30)

The dsRNA agent of claim 30, wherein the Y′ is 2′-O-methyl.

### Claim 32 (depends on 29)

The dsRNA agent of claim 29, wherein formula (III) is represented by formula (IIIa):
sense: 5′np-Na—YYY—Na-nq3′
antisense: 3′np′-Na′—Y′Y′Y′—Na′-nq′5′ (IIIa).

### Claim 33 (depends on 29)

The dsRNA agent of claim 29, wherein formula (III) is represented by formula (IIIb):
sense: 5′np-Na—YYY—Nb—ZZZ—Na-nq3′
antisense: 3′np′-Na′—Y′Y′Y′—Nb′—Z′Z′Z′—Na′-nq′5′ (IIIb)
wherein each Nb and Nb′ independently represents an oligonucleotide sequence comprising 1-5 modified nucleotides.

### Claim 34 (depends on 29)

The dsRNA agent of claim 29, wherein formula (III) is represented by formula (IIIc):
sense: 5′np-Na—XXX—Nb—YYY—Na-nq3′
antisense: 3′np′-Na′—X′X′X′—Nb′—Y′Y′Y′—Na′-nq′5′ (IIIc)
wherein each Nb and Nb′ independently represents an oligonucleotide sequence comprising 1-5 modified nucleotides.

### Claim 35 (depends on 29)

The dsRNA agent of claim 29, wherein formula (III) is represented by formula (IIId):
sense: 5′np-Na—XXX—Nb—YYY—Nb—ZZZ—Na-nq3′
antisense: 3′np′-Na′—X′X′X′—Nb′—Y′Y′Y′—Nb—Z′Z′Z′—Na′-nq′5′ (IIId)
wherein each Nb and Nb′ independently represents an oligonucleotide sequence comprising 1-5 modified nucleotides and each Na and Na′ independently represents an oligonucleotide sequence comprising 2-10 modified nucleotides.

### Claim 36 (depends on 7, 25)

The dsRNA agent of claim 7 or 25, wherein the double stranded region is 15-30 nucleotide pairs in length.

### Claim 37 (depends on 36)

The dsRNA agent of claim 36, wherein the double stranded region is 17-23 nucleotide pairs in length.

### Claim 38 (depends on 36)

The dsRNA agent of claim 36, wherein the double stranded region is 17-25 nucleotide pairs in length.

### Claim 39 (depends on 36)

The dsRNA agent of claim 36, wherein the double stranded region is 23-27 nucleotide pairs in length.

### Claim 40 (depends on 36)

The dsRNA agent of claim 36, wherein the double stranded region is 19-21 nucleotide pairs in length.

### Claim 41 (depends on 7, 25)

The dsRNA agent of claim 7 or 25, wherein the double stranded region is 21-23 nucleotide pairs in length.

### Claim 42 (depends on 25)

The dsRNA agent of claim 25, wherein each strand is 15-30 nucleotides in length.

### Claim 43 (depends on 7, 25)

The dsRNA agent of any one of claims 7, 25, and 35, wherein each strand is 19-30 nucleotides in length.

### Claim 44 (depends on 7, 25)

The dsRNA agent of claim 7 or 25, wherein the modifications on the nucleotides are selected from the group consisting of LNA, HNA, CeNA, 2′-methoxyethyl, 2′-O-alkyl, 2′-O-allyl, 2′-C-allyl, 2′-fluoro, 2′-deoxy, 2′-hydroxyl, and combinations thereof.

### Claim 45 (depends on 44)

The dsRNA agent of claim 44, wherein the modifications on the nucleotides are 2′-O-methyl or 2′-fluoro modifications.

### Claim 46 (depends on 7, 25)

The dsRNA agent of claim 7 or 25, wherein the ligand is one or more GalNAc derivatives attached through a monovalent, a bivalent or a trivalent branched linker.

### Claim 47 (depends on 25)

The dsRNA agent of claim 25, the ligand is

### Claim 48 (depends on 25)

The dsRNA agent of claim 25, wherein the ligand is attached to the 3′ end of the sense strand.

### Claim 49 (depends on 48)

The dsRNA agent of claim 48, wherein the RNAi agent is conjugated to the ligand as shown in the following schematic

### Claim 50 (depends on 7, 25)

The dsRNA agent of claim 7 or 25, wherein the agent further comprises at least one phosphorothioate or methylphosphonate internucleotide linkage.

### Claim 51 (depends on 50)

The dsRNA agent of claim 50, wherein the phosphorothioate or methylphosphonate internucleotide linkage is at the 3′-terminus of one strand.

### Claim 52 (depends on 51)

The dsRNA agent of claim 51, wherein the strand is the antisense strand.

### Claim 53 (depends on 51)

The dsRNA agent of claim 51, wherein the strand is the sense strand.

### Claim 54 (depends on 50)

The dsRNA agent of claim 50, wherein the phosphorothioate or methylphosphonate internucleotide linkage is at the 5′-terminus of one strand.

### Claim 55 (depends on 54)

The dsRNA agent of claim 54, wherein the strand is the antisense strand.

### Claim 56 (depends on 54)

The dsRNA agent of claim 54, wherein the strand is the sense strand.

### Claim 57 (depends on 50)

The dsRNA agent of claim 50, wherein the phosphorothioate or methylphosphonate internucleotide linkage is at the both the 5′- and 3′-terminus of one strand.

### Claim 58 (depends on 57)

The dsRNA agent of claim 57, wherein the strand is the antisense strand.

### Claim 59 (depends on 7, 25)

The dsRNA agent of claim 7 or 25, wherein the base pair at the 1 position of the 5′-end of the antisense strand of the duplex is an AU base pair.

### Claim 60 (depends on 25)

The dsRNA agent of claim 25, wherein the Y nucleotides contain a 2′-fluoro modification.

### Claim 61 (depends on 25)

The dsRNA agent of claim 25, wherein the Y′ nucleotides contain a 2′-O-methyl modification.

### Claim 62 (depends on 25)

The dsRNA agent of claim 25, wherein p′>0.

### Claim 63 (depends on 25)

The dsRNA agent of claim 25, wherein p′=2.

### Claim 64 (depends on 63)

The dsRNA agent of claim 63, wherein q′=0, p=0, q=0, and p′ overhang nucleotides are complementary to the target mRNA.

### Claim 65 (depends on 63)

The dsRNA agent of claim 63, wherein q′=0, p=0, q=0, and p′ overhang nucleotides are non-complementary to the target mRNA.

### Claim 66 (depends on 57)

The dsRNA agent of claim 57, wherein the sense strand has a total of 21 nucleotides and the antisense strand has a total of 23 nucleotides.

### Claim 67 (depends on 62, 63, 64, 65, 66)

The dsRNA agent of any one of claims 62-66, wherein at least one np′ is linked to a neighboring nucleotide via a phosphorothioate linkage.

### Claim 68 (depends on 67)

The dsRNA agent of claim 67, wherein all np′ are linked to neighboring nucleotides via phosphorothioate linkages.

### Claim 69 (depends on 25)

The dsRNA agent of claim 25, wherein the RNAi agent is selected from the group of RNAi agents listed in Table 3 or 5.

### Claim 70 (depends on 25)

The dsRNA agent of claim 25, wherein all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand comprise a modification.

### Claim 71

A double stranded ribonucleic acid (dsRNA) agent for inhibiting the expression of a ketohexokinase (KHK) gene in a cell, wherein the dsRNA agent comprises a sense strand and an antisense strand, wherein the sense strand comprises an at least 14 contiguous nucleotides of the nucleotide sequence of any one of nucleotides 89-107, 176-194, 264-282, 474-492, 508-526, 529-547, 562-580, 616-646, 682-700, 705-723, 705-757, 705-799, 739-757, 739-799, 760-799, 804-822, 837-855, 892-910, 959-977, 992-1010, 922-1041, 1013-1041, 1069-1108, 1169-1140, 1111-1140, 1155-1196, 1221-1261, 1267-1294, or 1320-1350 of SEQ ID NO: 1, and wherein the antisense strand comprises a region of complementarity to an mRNA encoding KHK, wherein each strand is about 14 to about 30 nucleotides in length, wherein the dsRNA agent is represented by formula (III):
sense: 5′np-Na—(XXX)i—Nb—YYY—Nb—(ZZZ)j—Na-nq3′
antisense: 3′np′-Na′—(X′X′X′)k—Nb′—Y′Y′Y′—Nb′—(Z′Z′Z′)l—Na′-nq′5′ (III)
wherein:
j, k, and l are each independently 0 or 1;
p, p′, q, and q′ are each independently 0-6;
each Na and Na′ independently represents an oligonucleotide sequence comprising 0-25 nucleotides which are either modified or unmodified or combinations thereof, each sequence comprising at least two differently modified nucleotides;
each Nb and Nb′ independently represents an oligonucleotide sequence comprising 0-10 nucleotides which are either modified or unmodified or combinations thereof;
each np, np′, nq, and nq′, each of which may or may not be present independently represents an overhang nucleotide;
XXX, YYY, ZZZ, X′X′X′, Y′Y′Y′, and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides, and wherein the modifications are 2′-O-methyl or 2′-fluoro modifications;
modifications on Nb differ from the modification on Y and modifications on Nb′ differ from the modification on Y′; and
wherein the sense strand is conjugated to at least one ligand.

### Claim 72

A double stranded ribonucleic acid (dsRNA) agent for inhibiting the expression of a ketohexokinase (KHK) gene in a cell, wherein the dsRNA agent comprises a sense strand and an antisense strand, wherein the sense strand comprises at least 14 contiguous nucleotides of the nucleotide sequence of any one of nucleotides 89-107, 176-194, 264-282, 474-492, 508-526, 529-547, 562-580, 616-646, 682-700, 705-723, 705-757, 705-799, 739-757, 739-799, 760-799, 804-822, 837-855, 892-910, 959-977, 992-1010, 922-1041, 1013-1041, 1069-1108, 1169-1140, 1111-1140, 1155-1196, 1221-1261, 1267-1294, or 1320-1350 of SEQ ID NO: 1, and wherein the antisense strand comprises a region of complementarity to an mRNA encoding KHK, wherein each strand is about 14 to about 30 nucleotides in length, wherein the dsRNA agent is represented by formula (III):
sense: 5′np-Na—(XXX)i—Nb—YYY—Nb—(ZZZ)j—Na-nq3′
antisense: 3′np′-Na′—(X′X′X′)k—Nb′—Y′Y′Y′—Nb′—(Z′Z′Z′)l—Na′-nq′5′ (III)
wherein:
j, k, and l are each independently 0 or 1;
each np, nq, and nq′, each of which may or may not be present, independently represents an overhang nucleotide;
p, q, and q′ are each independently 0-6;
np′>0 and at least one np′ is linked to a neighboring nucleotide via a phosphorothioate linkage;
each Na and Na′ independently represents an oligonucleotide sequence comprising 0-25 nucleotides which are either modified or unmodified or combinations thereof, each sequence comprising at least two differently modified nucleotides;
each Nb and Nb′ independently represents an oligonucleotide sequence comprising 0-10 nucleotides which are either modified or unmodified or combinations thereof;
XXX, YYY, ZZZ, X′X′X′, Y′Y′Y′, and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides, and wherein the modifications are 2′-O-methyl or 2′-fluoro modifications;
modifications on Nb differ from the modification on Y and modifications on Nb′ differ from the modification on Y′; and
wherein the sense strand is conjugated to at least one ligand.

### Claim 73

A double stranded ribonucleic acid (dsRNA) agent for inhibiting the expression of a ketohexokinase (KHK) gene in a cell, wherein the dsRNA agent comprises a sense strand and an antisense strand, wherein the sense strand comprises at least 14 contiguous nucleotides of the nucleotide sequence of any one of nucleotides 89-107, 176-194, 264-282, 474-492, 508-526, 529-547, 562-580, 616-646, 682-700, 705-723, 705-757, 705-799, 739-757, 739-799, 760-799, 804-822, 837-855, 892-910, 959-977, 992-1010, 922-1041, 1013-1041, 1069-1108, 1169-1140, 1111-1140, 1155-1196, 1221-1261, 1267-1294, or 1320-1350 of SEQ ID NO: 1, and wherein the antisense strand comprises a region of complementarity to an mRNA encoding KHK, wherein each strand is about 14 to about 30 nucleotides in length, wherein the dsRNA agent is represented by formula (III):
sense: 5′np-Na—(XXX)i—Nb—YYY—Nb—(ZZZ)j—Na-nq3′
antisense: 3′np′-Na′—(X′X′X′)k—Nb′—Y′Y′Y′—Nb′—(Z′Z′Z′)l—Na′-nq′5′ (III)
wherein:
j, k, and l are each independently 0 or 1;
each np, nq, and nq′, each of which may or may not be present, independently represents an overhang nucleotide;
p, q, and q′ are each independently 0-6;
np′>0 and at least one np′ is linked to a neighboring nucleotide via a phosphorothioate linkage;
each Na and Na′ independently represents an oligonucleotide sequence comprising 0-25 nucleotides which are either modified or unmodified or combinations thereof, each sequence comprising at least two differently modified nucleotides;
each Nb and Nb′ independently represents an oligonucleotide sequence comprising 0-10 nucleotides which are either modified or unmodified or combinations thereof;
XXX, YYY, ZZZ, X′X′X′, Y′Y′Y′, and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides, and wherein the modifications are 2′-O-methyl or 2′-fluoro modifications;
modifications on Nb differ from the modification on Y and modifications on Nb′ differ from the modification on Y′; and
wherein the sense strand is conjugated to at least one ligand, wherein the ligand is one or more GalNAc derivatives attached through a monovalent, a bivalent or a trivalent branched linker.

### Claim 74

A double stranded ribonucleic acid (dsRNA) agent for inhibiting the expression of a ketohexokinase (KHK) gene in a cell, wherein the dsRNA agent comprises a sense strand and an antisense strand, wherein the sense strand comprises at least 14 contiguous nucleotides of the nucleotide sequence of any one of nucleotides 89-107, 176-194, 264-282, 474-492, 508-526, 529-547, 562-580, 616-646, 682-700, 705-723, 705-757, 705-799, 739-757, 739-799, 760-799, 804-822, 837-855, 892-910, 959-977, 992-1010, 922-1041, 1013-1041, 1069-1108, 1169-1140, 1111-1140, 1155-1196, 1221-1261, 1267-1294, or 1320-1350 of SEQ ID NO: 1, and wherein the antisense strand comprises a region of complementarity to an mRNA encoding KHK, wherein each strand is about 14 to about 30 nucleotides in length, wherein the dsRNA agent is represented by formula (III):
sense: 5′np-Na—(XXX)i—Nb—YYY—Nb—(ZZZ)j—Na-nq3′
antisense: 3′np′-Na′—(X′X′X′)k—Nb′—Y′Y′Y′—Nb′—(Z′Z′Z′)l—Na′-nq′5′ (III)
wherein:
j, k, and l are each independently 0 or 1;
each np, nq, and nq′, each of which may or may not be present, independently represents an overhang nucleotide;
p, q, and q′ are each independently 0-6;
np′>0 and at least one np′ is linked to a neighboring nucleotide via a phosphorothioate linkage;
each Na and Na′ independently represents an oligonucleotide sequence comprising 0-25 nucleotides which are either modified or unmodified or combinations thereof, each sequence comprising at least two differently modified nucleotides;
each Nb and Nb′ independently represents an oligonucleotide sequence comprising 0-10 nucleotides which are either modified or unmodified or combinations thereof;
XXX, YYY, ZZZ, X′X′X′, Y′Y′Y′, and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides, and wherein the modifications are 2′-O-methyl or 2′-fluoro modifications;
modifications on Nb differ from the modification on Y and modifications on Nb′ differ from the modification on Y′;
wherein the sense strand comprises at least one phosphorothioate linkage; and
wherein the sense strand is conjugated to at least one ligand, wherein the ligand is one or more GalNAc derivatives attached through a monovalent, a bivalent or a trivalent branched linker.

### Claim 75

A double stranded ribonucleic acid (dsRNA) agent for inhibiting the expression of a ketohexokinase (KHK) gene in a cell, wherein the dsRNA agent comprises a sense strand and an antisense strand, wherein the sense strand comprises at least 14 contiguous nucleotides of the nucleotide sequence of any one of nucleotides 89-107, 176-194, 264-282, 474-492, 508-526, 529-547, 562-580, 616-646, 682-700, 705-723, 705-757, 705-799, 739-757, 739-799, 760-799, 804-822, 837-855, 892-910, 959-977, 992-1010, 922-1041, 1013-1041, 1069-1108, 1169-1140, 1111-1140, 1155-1196, 1221-1261, 1267-1294, or 1320-1350 of SEQ ID NO: 1, and wherein the antisense strand comprises a region of complementarity to an mRNA encoding KHK, wherein each strand is about 14 to about 30 nucleotides in length, wherein the dsRNA agent is represented by formula (III):
sense: 5′np-Na—YYY—Na-nq3′
antisense: 3′np′-Na′—Y′Y′Y′—Na′-nq′5′ (IIIa)
wherein:
each np, nq, and nq′, each of which may or may not be present, independently represents an overhang nucleotide;
p, q, and q′ are each independently 0-6;
np′>0 and at least one np′ is linked to a neighboring nucleotide via a phosphorothioate linkage;
each Na and Na′ independently represents an oligonucleotide sequence comprising 0-25 nucleotides which are either modified or unmodified or combinations thereof, each sequence comprising at least two differently modified nucleotides;
YYY and Y′Y′Y′ each independently represent one motif of three identical modifications on three consecutive nucleotides, and wherein the modifications are 2′-O-methyl or 2′-fluoro modifications;
wherein the sense strand comprises at least one phosphorothioate linkage; and
wherein the sense strand is conjugated to at least one ligand, wherein the ligand is one or more GalNAc derivatives attached through a monovalent, a bivalent or a trivalent branched linker.

### Claim 76

A double stranded ribonucleic acid (dsRNA) agent for inhibiting the expression of a ketohexokinase (KHK) gene in a cell,
wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region,
wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of any one of nucleotides 89-107, 176-194, 264-282, 474-492, 508-526, 529-547, 562-580, 616-646, 682-700, 705-723, 705-757, 705-799, 739-757, 739-799, 760-799, 804-822, 837-855, 892-910, 959-977, 992-1010, 922-1041, 1013-1041, 1069-1108, 1169-1140, 1111-1140, 1155-1196, 1221-1261, 1267-1294, or 1320-1350 of the nucleotide sequence of SEQ ID NO:1 and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the corresponding nucleotide sequence of SEQ ID NO:2,
wherein substantially all of the nucleotides of the sense strand comprise a modification selected from the group consisting of a 2′-O-methyl modification and a 2′-fluoro modification,
wherein the sense strand comprises two phosphorothioate internucleotide linkages at the 5′-terminus,
wherein substantially all of the nucleotides of the antisense strand comprise a modification selected from the group consisting of a 2′-O-methyl modification and a 2′-fluoro modification,
wherein the antisense strand comprises two phosphorothioate internucleotide linkages at the 5′-terminus and two phosphorothioate internucleotide linkages at the 3′-terminus, and
wherein the sense strand is conjugated to one or more GalNAc derivatives attached through a monovalent, a bivalent or a trivalent branched linker at the 3′-terminus.

### Claim 77 (depends on 76)

The dsRNA agent of claim 76, wherein all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand are modified nucleotides.

### Claim 78 (depends on 76)

The dsRNA agent of claim 76, wherein each strand is 19-30 nucleotides in length.

### Claim 79 (depends on 1, 2, 3, 7, 25)

A cell containing the dsRNA agent of any one of claim 1-3, 7, 25, or 70-75.

### Claim 80 (depends on 1, 2, 3, 7, 24)

A pharmaceutical composition for inhibiting expression of a ketohexokinase (KHK) gene comprising the dsRNA agent of any one of claim 1-3, 7, 24, or 70-75.

### Claim 81 (depends on 1, 2, 3)

A pharmaceutical composition comprising the dsRNA agent of any one of claims 1-3, and a lipid formulation.

### Claim 82 (depends on 81)

The pharmaceutical composition of claim 81, wherein the lipid formulation comprises a LNP or an MC3.

### Claim 83 (depends on 1, 2, 3, 7, 25, 80, 81, 82)

A method of inhibiting expression of a ketohexokinase (KHK) gene in a cell, the method comprising:
(a) contacting the cell with the double stranded RNAi agent of any one of claims 1-3, 7, 25, and 71-76 or a pharmaceutical composition of any one of claims 80-82; and
(b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of the KHK gene, thereby inhibiting expression of the KHK gene in the cell.

### Claim 84 (depends on 83)

The method of claim 83, wherein the cell is within a subject.

### Claim 85 (depends on 84)

The method of claim 84, wherein the subject is a human.

### Claim 86 (depends on 83, 84, 85)

The method of any one of claims 83-85, wherein the expression of KHK is inhibited by at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or to below the threshold of detection as compared to an appropriate control.

### Claim 87 (depends on 1, 2, 3, 7, 25, 80, 81, 82)

A method of treating a subject having a disease or disorder that would benefit from reduction in expression of ketohexokinase (KHK), the method comprising administering to the subject a therapeutically effective amount of the dsRNA agent of any one of claims 1-3, 7, 25, and 71-76 or a pharmaceutical composition of any one of claims 80-82, thereby treating the subject.

### Claim 88 (depends on 1, 2, 3, 7, 25, 80, 81, 82)

A method of preventing at least one symptom in a subject having a disease or disorder that would benefit from reduction in expression of ketohexokinase (KHK), the method comprising administering to the subject a prophylactically effective amount of the dsRNA agent of any one of claims 1-3, 7, 25, and 71-76 or a pharmaceutical composition of any one of claims 80-82, thereby preventing at least one symptom in the subject having a disorder that would benefit from reduction in expression of KHK.

### Claim 89 (depends on 87, 88)

The method of claim 87 or 88, wherein the administration of the dsRNA to the subject causes a decrease in fructose metabolism.

### Claim 90 (depends on 87, 88)

The method of claim 87 or 88, wherein the disorder is a KHK-associated disease.

### Claim 91 (depends on 90)

The method of claim 90, wherein the KHK-associated disease comprises hyperuricemia.

### Claim 92 (depends on 90)

The method of claim 90, wherein the KHK-associated disease is gout.

### Claim 93 (depends on 90)

The method of claim 90, wherein the KHK-associated disease comprises liver disease.

### Claim 94 (depends on 93)

The method of claim 93, wherein the liver disease is non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).

### Claim 95 (depends on 90)

The method of claim 90, wherein the KHK-associated disease comprises dyslipidemia or abnormal lipid deposition or dysfunction.

### Claim 96 (depends on 95)

The method of claim 95, wherein dyslipidemia comprises one or more of hyperlipidemia, high LDL cholesterol, low HDL cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia, adipocyte dysfunction, visceral adipose deposition, obesity, and metabolic syndrome.

### Claim 97 (depends on 90)

The method of claim 90, wherein the KHK-associated disease comprises a disorder of glycemic control.

### Claim 98 (depends on 97)

The method of claim 97, wherein the disorder of glycemic control comprises one or more of insulin resistance not related to immune response to insulin, type 2 diabetes, and glucose intolerance.

### Claim 99 (depends on 90)

The method of claim 90, wherein the KHK-associated disease comprises kidney disease.

### Claim 100 (depends on 93)

The method of claim 93, wherein the liver disease comprises at least one of acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules, and chronic kidney disease.

### Claim 101 (depends on 90)

The method of claim 90, wherein the KHK-associated disease comprises cardiovascular disease.

### Claim 102 (depends on 101)

The method of claim 101, wherein the cardiovascular disease comprises at least one of hypertension and endothelial cell dysfunction.

### Claim 103 (depends on 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102)

The method of any one of claims 87-102, wherein the subject is human.

### Claim 104 (depends on 103)

The method of claim 103, wherein the subject has or is prone to compromised renal function.

### Claim 105 (depends on 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104)

The method of any one of claims 87-104, further comprising administering an agent for the treatment of a KHK-associated disease.

### Claim 106 (depends on 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105)

The method of any one of claims 87-105, wherein the dsRNA agent is administered at a dose of about 0.01 mg/kg to about 50 mg/kg.

### Claim 107 (depends on 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106)

The method of any one of claims 87-106, wherein the dsRNA agent is administered to the subject subcutaneously.

### Claim 108 (depends on 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107)

The method of claim 87-107, further comprising measuring a level of KHK in the subject.

### Claim 109 (depends on 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108)

The method of claim 87-108, further comprising measuring a level of fructose metabolism in the subject.

### Claim 110 (depends on 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109)

The method of claim 87-109, further comprising measuring a uric acid level in the subject.

### Claim 111 (depends on 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110)

The method of claim 87-110, further comprising measuring a serum lipid level in the subject.
